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In a previous study, we showed that EGFR mutation status in serum 
DNA was useful as a predictor of response to geﬁtinib (IRESSA). The 
aim of this study was to assess the feasibility of detecting EGFR muta-
tions in serum DNA and to evaluate the usefulness of EGFR mutation 
status in serum DNA as a means of predicting a beneﬁt from geﬁtinib 
therapy in Japanese patients with NSCLC. We obtained pairs of tumor 
and serum samples from 42 patients treated with geﬁtinib and exam-
ined them for EGFR mutations. EGFR mutation status was determined 
by a direct sequencing method and by Scorpion Ampliﬁcation Refrac-
tory Mutation System (ARMS) technology. EGFR mutations were de-
tected in the tumor samples of eight patients and in the serum samples 
of seven patients. EGFR mutation status in the tumors and serum 
samples was consistent in 39 (92.9%) of the 42 pairs. EGFR! mutations 
were more frequent in women and non-smokers, and there were strong 
correlations between both EGFR mutation status in the tumor samples 
and serum samples, and objective response to geﬁtinib (p<0.001, Fish-
er’s exact test). Median progression-free survival time was signiﬁcantly 
longer in the patients with EGFR mutations than in the patients without 
EGFR mutations (194 vs. 55 days, P=0.016, in tumor samples; 174 vs. 
58 days, P=0.044, in serum samples, Log-rank test). Median survival 
time was longer in the patients with EGFR mutations detected by either 
of the two methods than in the patients without EGFR mutations, but 
the difference was not statistically signiﬁcant. The results suggest that 
it is feasible to use serum DNA to detect EGFR mutations, and that 
it’s potential as a predictor of response to, and survival on geﬁtinib is 
worthy of further evaluation.
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Background: Somatic EGFR gene mutations are reported to be associ-
ated with clinical responses to geﬁtinib and erlotinib in patients with 
non-small cell lung cancer (NSCLC). Retrospective studies have shown 
around 75% response rate in patients with tumors that have EGFR gene 
mutations compared with a response rate of less than 10% in those with 
wild-type EGFR. We prospectively examined the status of EGFR gene 
mutations in patients with NSCLC and their response to treatment with 
geﬁtinib. 
Methods: Clinical samples (formalin-ﬁxed parafﬁn-embedded tumor 
tissue, pleural effusion, and sputum) were obtained with informed con-
sent from patients with advanced NSCLC at Toranomon Hospital, and 
were examined for EGFR mutations by direct sequencing or the peptide 
nucleic acid-locked nucleic acid PCR clamp method (Cancer Res. 
2005;65:7276). Patients who received geﬁtinib therapy after examin-
ing EGFR mutations were then evaluated for their response to geﬁtinib 
according to RECIST criteria. 
Results: Tumor samples from 60 patients who were enrolled in the 
study from June 2006 to January 2007 were analyzed. EGFR muta-
tions were detected in 17 of 60 patients (28.3%) (13 females/4 males; 
16 never-smokers/ 1 former-smoker; all adenocarcinomas). Detected 
mutations included 9- to 18-base deletion in exon 19 in 12 patients 
(70.6%), L858R in exon 21 in 4 (23.5%) and an 18-base insertion in 
exon 19 in 1 (5.9%), respectively. Ten of 17 patients with EGFR muta-
tions were given geﬁtinib 250 mg daily (median age: 67 years; 9 fe-
males/1 male; all never-smokers; performance status 0-1/2-4=6/4; stage 
IIIB/IV/postoperative recurrence=2/3/5). Four patients were treated 
with geﬁtinib as the ﬁrst-line therapy. Nine patients had measurable le-
sions, and the response to geﬁtinib was PR in four patients, SD in three, 
and PD in two, respectively. The response rate and disease control 
rate were 44.4% and 77.8%, respectively. On the other hand, four of 
43 patients with wild-type EGFR received geﬁtinib, but none of these 
patients achieved CR or PR. No signiﬁcant adverse events (>grade 3) 
including acute lung injury/interstitial pneumonia were observed. 
Conclusion: EGFR mutations were found in the tumors of 28% of 
Japanese patients with NSCLC. The disease control rate of geﬁtinib 
therapy was extremely good in those who had EGFR mutations. Thus, 
routine evaluation for the EGFR mutation status is desirable in patients 
with NSCLC before treatment of geﬁtinib. 
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Background: Erlotinib as single agent is associated with objective 
response rates of about 12% in unselected patients with NSCLC stage 
IIIB/IV. Much higher response rates were observed in selected groups 
of patients selected on the basis of EGFR mutations. To investigate 
whether erlotinib is able to make an extra contribution to surgical 
treatment of early stage NSCLC, a phase II study was initiated in the 
Netherlands. This study is meant to provide a proof of principle if erlo-
tinib is a worthwhile induction therapy option and if erlotinib may be 
advised as induction regimen for a selected group of patients. We report 
a remarkable response in one of our ﬁrst patients.
Case Presentation: A 58-year old woman presenting with a clinical 
stage I adenocarcinoma in the right upper lobe was asked to participate 
in the study. After written informed consent, she received erlotinib for 
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3 weeks according to protocol and consecutively underwent surgical re-
section. Radiological and metabolic response was measured by [18F]-
FDG-PET/CT after 3 and 21 days, and postoperatively the pathological 
response was assessed in the resection specimen. 
Results: Our patient had developed grade 2 skin toxicity in the third 
week of erlotinib treatment. Evaluation after 3 days and 21 days with 
[18F]-FDG-PET showed no appreciable metabolic response and stable 
disease on CT. A lobectomy of the right upper lobe with lymph node 
dissection was carried out. Pathological evaluation showed strong 
ﬁbrotic degeneration of the original tumor, with a vital rest of less 
than 10%. All lymph nodes were free of tumor. The low percentage of 
tumor cells did not allow for EGFR mutation analysis. There were no 
postoperative complications, and skin toxicity dissolved spontaneously 
after cessation of erlotinib.
Conclusions: In this patient with stage I adenocarcinoma of the right 
lung, receiving 3 weeks of preoperative erlotinib resulted in near com-
plete pathologic response. This result shows that erlotinib could be a 
potent agent in neoadjuvant and/or adjuvant setting in the treatment of 
non-small cell lung cancer.
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Background: Somatic mutations in the epidermal growth factor recep-
tor (EGFR) gene have been reported to be present in non-small-cell 
lung cancer, and associated with sensitivity of tumors to EGFR tyrosine 
kinase inhibitors. We previously reported on positive correlation of 
EGFR mutations with effectiveness of geﬁtinib treatment in 59 patients 
with recurrence after pulmonary resection (JCO, 23: 2513-2510, 2005). 
Here, we report the result of updated analysis based on 103 patients, 
adding 44 patients, with longer follow-up.
Methods: We sequenced exons 18-21 of the EGFR gene using total 
RNA extracted from 103 patients with lung cancer who were treated 
with geﬁtinib for their recurrent disease. Because this study was a retro-
spective analysis of clinical practice, the evaluation of tumor response 
could not be performed strictly according to Response Evaluation Cri-
teria in Solid Tumors. Therefore tumor response to geﬁtinib treatment 
was evaluated by both the imaging studies and the change in serum 
carcinoembryonic antigen (CEA). Geﬁtinib treatment was judged as 
effective when the tumors showed at least a 30% decrease in tumor 
diameter or when the elevated serum CEA level decreased to a level 
less than half of the baseline level.
Results: EGFR mutations were detected in 61 of 103 tumors (59%). Of 
them, 31 were exon 19 deletions, 22 were L858R, three were G719X, 
three were insertions in exons 19 or 20, and two were other types of 
point mutations. Mutations were signiﬁcantly frequent in female (72% 
in female, 48% in male) (P=0.0131, χ2 test), never-smokers (73% in 
never-smokers, 48% in former or current smokers) (P=0.0082), and the 
patients with adenocarcinomas (65% in adenocarcinomas, 17% in non-
adenocarcinomas) (P=0.0031). The response to geﬁtinib treatment was 
assessable in 88 patients, and 51 patients were evaluated as effective 
(the response rate (RR) was 58%). The RR in the patients with EGFR 
mutations was 83% (45 of 54 patients was effective), whereas the RR 
in those without mutation was 18% (6 of 34 patients was effective). 
Logistic regression analysis using various factors (sex, age, smoking 
status, histology, existence of prior chemotherapy, pathological stage, 
status of EGFR mutation) showed that EGFR mutation (odds ratio 
53.666, P<0.0001) and absence of prior chemotherapy (odds ratio 
5.979, P=0.0143) were signiﬁcant factors contributing to the response. 
Patients with EGFR mutation survived for a signiﬁcant longer period 
than those without mutations after geﬁtinib treatment (MST, 30.1 
versus 10.6 month; P=0.0038, log-rank test). When the patients with 
EGFR mutation were divided to subgroups according to the types of 
EGFR mutations, the RRs of each group were differed (93% in exon 19 
deletions, 75% in L858R, 67% in G719X, and 0% in exon 19 inser-
tion). However, there was no difference in overall survival after geﬁ-
tinib treatment between the patients with two major types of mutation 
(MST, 36.0 month in exon 19 deletions versus 33.1 month in L858R; 
P=0.7247).
Conclusions: We conﬁrmed that the tumors with EGFR mutations 
showed good correlation with clinical response to geﬁtinib treatment 
in patients with recurrent lung cancer after pulmonary resection in this 
updated analysis. Furthermore, we found that there were differences in 
the RR among the classes of mutations.
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Background: The current standard of care for advanced stage NSCLC 
is platinum-based doublet chemotherapy. Bevacizumab (BV) is a 
recombinant, humanized anti-vascular endothelial growth factor mono-
clonal antibody with proven efﬁcacy in cancer therapy. In advanced 
NSCLC, the addition of bevacizumab 15 mg/kg every 3 weeks to pacli-
taxel/carboplatin (PC) prolonged survival and progression-free survival 
(PFS), and improved PFS (survival data pending) when combined with 
cisplatin/gemcitabine (Sandler N Engl J Med. 2006, Genentech press 
release). 
Methods: In the present studies, we are using BV 15 mg/kg day 1 in 
combination with gemcitabine (G) 1000 mg/m2 days 1 and 8, and car-
boplatin (C) AUC5 day 1 for the treatment of NSCLC. Eligible pts with 
stage IIIB-IV NSCLC, PS 0-1, and adequate hematologic, renal and he-
patic function, have been enrolled. Pts with squamous cell carcinoma, 
tumor in the central airways, baseline hemoptysis, or brain metastases 
are excluded; IIIB pts had malignant effusion. GC/BV treatment was 
given in q 3-weekly cycles for 4- 6 cycles, with BV continued in stable 
and responding patients until progression. One of the studies was 
amended after 7 pts were enrolled to reduce the dose of G from 1250 
to 1000 mg/m2 on days 1 and 8 due to unacceptable neutropenia. Only 
data from patients treated after the dose reduction is presented. To date, 
17 pts in one trial and 12 pts in the other have received at least 2 cycles 
of combination therapy; we report here the hematologic and non-hema-
tologic toxicity of these pts. 
